Phase I trial of bortezomib in combination with rituximab-HyperCVAD/methotrexate and cytarabine for untreated mantle cell lymphoma

被引：0
|
作者：
Romaguera, J. E. [1 ]
Pro, B. [1 ]
Fayad, L. [1 ]
McLaughlin, P. [1 ]
Wang, M. [1 ]
Weaver, P. [1 ]
Hartig, K. [1 ]
Hagemeister, F. [1 ]
Rodriguez, M. A. [1 ]
Younes, A. [1 ]
Samaniego, F. [1 ]
Fanale, M. [1 ]
Kwak, L. [1 ]
Feldman, T. [2 ]
Goy, A. [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Hackensack Univ, Med Ctr, Hackensack, NJ USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：214 / 214
页数：1
相关论文
共 50 条
  • [1] Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma
    Romaguera, Jorge
    Fayad, Luis
    McLaughlin, Peter
    Pro, Barbara
    Rodriguez, Maria Alma
    Wang, Michael
    Weaver, Pamela
    Hartig, Kimberly
    Kwak, Larry
    Feldman, Tatyana
    Smith, Judy
    Ford, Peggy
    Goldberg, Stuart
    Pecora, Andrew
    Goy, Andre
    BLOOD, 2008, 112 (11) : 1049 - 1049
  • [2] Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
    Romaguera, Jorge E.
    Fayad, Luis E.
    McLaughlin, Peter
    Pro, Barbara
    Rodriguez, Alma
    Wang, Michael
    Weaver, Pamela
    Hartig, Kimberly
    Kwak, Larry W.
    Feldman, Tatyana
    Smith, Judy
    Ford, Peggy
    Goldberg, Stuart
    Pecora, Andrew
    Goy, Andre
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 151 (01) : 47 - 53
  • [3] Phase 2 Trial of Bortezomib in Combination With Rituximab Plus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Alternating With Bortezomib, Rituximab, Methotrexate, and Cytarabine for Untreated Mantle Cell Lymphoma
    Romaguera, Jorge E.
    Wang, Michael
    Feng, Lei
    Fayad, Luis E.
    Hagemeister, Frederick
    McLaughlin, Peter
    Rodriguez, M. Alma
    Fanale, Michelle
    Orlowski, Robert
    Kwak, Larry W.
    Neelapu, Sattva
    Oki, Yasuhiro
    Pro, Barbara
    Younes, Anas
    Samaniego, Felipe
    Fowler, Nathan
    Hartig, Kimberly
    Valentinetti, Marisa
    Smith, Judy
    Ford, Peggy
    Naig, Adam
    Medeiros, L. Jeffrey
    Kantarjian, Hagop M.
    Goy, Andre
    CANCER, 2018, 124 (12) : 2561 - 2569
  • [4] Methotrexate/cytarabine only as initial management of untreated mantle cell lymphoma: Results of a phase IICCOP trial
    Romaguera, J. E.
    Flynn, P. J.
    Hasler, G. R.
    ANNALS OF ONCOLOGY, 2008, 19 : 213 - 213
  • [5] PHASE I-II STUDY OF BORTEZOMIB IN COMBINATION WITH R-HCVAD AND R-METHOTREXATE/CYTARABINE (R-MA) IN UNTREATED MANTLE CELL LYMPHOMA (MCL)
    Romaguera, J. E.
    Wang, M.
    Hagemeister, F.
    Weaver, P.
    Hartig, K.
    Fanale, M.
    Fayad, L. E.
    Feldman, T.
    Fowler, N.
    Orlowski, R.
    Smith, J.
    Ford, P.
    Ekaney, M.
    Kwak, L. W.
    Goy, A.
    ANNALS OF ONCOLOGY, 2011, 22 : 163 - 163
  • [6] Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Romaguera, Jorge E.
    Fayad, Luis E.
    Feng, Lei
    Hartig, Kimberly
    Weaver, Pamela
    Rodriguez, Maria Alma
    Hagemeister, Fredrick B.
    Pro, Barbara
    McLaughlin, Peter
    Younes, Anas
    Samaniego, Felipe
    Goy, Andre
    Cabanillas, Fernando
    Kantarjian, Hagop
    Kwak, Larry
    Wang, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (02) : 200 - 208
  • [7] Rituximab Plus Hypercvad Alternating with High Dose Methotrexate and Cytarabine for Patients with Newly Diagnosed Mantle Cell Lymphoma. A Multicenter Trial from GISL
    Merli, Francesco
    Luminari, Stefano
    Ilariucci, Fiorella
    Stelitano, Caterina
    Petrini, Mario
    Di Renzo, Nicola
    Angrilli, Francesco
    Carella, Angelo Michele
    Barbolini, Elisa
    Federico, Massimo
    BLOOD, 2008, 112 (11) : 1048 - 1049
  • [8] First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group
    Arranz, Reyes
    Garcia-Noblejas, Ana
    Grande, Carlos
    Cannata-Ortiz, Jimena
    Sanchez, Jose J.
    Garcia-Marco, Jose-Antonio
    Alaez, Concepcion
    Perez-Calvo, Javier
    Martinez-Sanchez, Pilar
    Sanchez-Gonzalez, Blanca
    Canales, Miguel-Angel
    Conde, Eulogio
    Martin, Alejandro
    Arranz, Eva
    Terol, Maria-Jose
    Salar, Antonio
    Caballero, Dolores
    HAEMATOLOGICA, 2013, 98 (10) : 1563 - 1570
  • [9] A Pilot Study of Acalabrutinib With Bendamustine/Rituximab Followed by Cytarabine/Rituximab for Untreated Mantle Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 12 - 12
  • [10] A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213
    Bernstein, S. H.
    Epner, E.
    Unger, J. M.
    LeBlanc, M.
    Cebula, E.
    Burack, R.
    Rimsza, L.
    Miller, T. P.
    Fisher, R. I.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1587 - 1593
12345